tribu Sans peur Raffinement hetero visa au moins Spécialiser Cassecroûte
14th March 2013 Susceptibility testing for Vancomycin in S. aureus : What do we do now? Robin A Howe Antimicrobial use in Primary Care. - ppt download
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis | Scientific Reports
Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections | Annals of Clinical Microbiology and Antimicrobials | Full Text
Population analysis profile of VISA, hetero-VISA, and VSMRSA.... | Download Scientific Diagram
Vancomycin-intermediate resistance in Staphylococcus aureus - ScienceDirect
PDF] Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. | Semantic Scholar
Vancomycin-intermediate resistance in Staphylococcus aureus - ScienceDirect
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis | Scientific Reports
Detection of Staphylococcus aureus with reduced susceptibility to vancomycin in a South African teaching hospital
Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study | Antimicrobial Resistance & Infection
Association between cell growth and vancomycin resistance in clinical community-associated methicillin-resistant Staphylococcus aureus - Document - Gale Academic OneFile
Drug Class Review Monograph – GPI Class 02 – Cephalosporins
Vancomycin-intermediate resistance in Staphylococcus aureus - ScienceDirect
Hetero-intermediate Staphylococcus aureus
Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives – CIBFar
Acknowledgements References Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VIS
2. Population analysis of the vancomycinintermediate Staphylococcus... | Download Scientific Diagram
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis | Scientific Reports
Vancomycin-intermediate resistance in Staphylococcus aureus - ScienceDirect
Ceftaroline fosamil: drug profile and clinical data
Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital
xmlinkhub
Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis | Scientific Reports